The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) and Gamaleya National Research Center of Epidemiology and Microbiology today announced the results of an efficacy analysis of the one-shot Sputnik Light vaccine against infection from the Delta variant of coronavirus.
Gamaleya Center has submitted an article analyzing efficacy of Sputnik Light vaccine against the Delta variant to the medRxiv preprint server for health sciences for publication this week.
I. Efficacy of Sputnik Light as a standalone vaccine
The article states that the Sputnik Light vaccine administered alone has demonstrated 70% efficacy against infection from the Delta variant of coronavirus during the first three months after vaccination. The vaccine is 75% effective among subjects under the age of 60. Sputnik Light has demonstrated a superior efficacy compared with some two-shot vaccines, which have shown a major decline in efficacy against the Delta variant to less than 50% five months after injection.
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations.
The analysis was conducted based on data from 28,000 participants who had received a single dose of Sputnik Light, compared with a control group of 5.6 million individuals who were not vaccinated. The data used in the study was collected in July 2021 in Moscow.
II. Efficacy of Sputnik Light as a booster shot
A one-shot vaccination regimen of Sputnik Light has a number of key advantages, including ease of administering the vaccine, monitoring and more flexible re-vaccination schedule when used as a booster.
Efficacy of one-shot Sputnik Light as a booster against Delta variant for other vaccines will be close to the efficacy against the Delta variant of the Sputnik V vaccine: over 83% against infection and over 94% against hospitalization.
III. Real-world data on Sputnik Light and studies of combination with other vaccines
The Sputnik Light vaccine is based on the human adenovirus serotype 26, the first component of Sputnik V – the world's first registered vaccine against coronavirus. Sputnik Light has been authorized in more than 15 countries with the registration process ongoing in a further 30 countries. Sputnik Light will be produced by RDIF's international partners in more than 10 countries (India, China, South Korea, Vietnam, Mexico, Argentina, Serbia, Turkey, etc.). This includes the Serum Institute of India, the world's largest vaccine producer.
Sputnik Light has been proven to be safe and highly effective by real-world vaccination data in a number of countries. In particular, the vaccine has demonstrated efficacy of between 78.6-83.7% among the elderly as confirmed by the Ministry of Health of Buenos Aires, Argentina. Paraguay's Ministry of Health also found Sputnik Light to be 93.5% effective during the country's ongoing vaccination campaign.
Thanks to its safety and efficacy, the one-shot Sputnik Light vaccine is now used both on a standalone basis and studied in combination with vaccines from other producers in multiple countries.
The heterogeneous boosting approach (a "vaccine cocktail" using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component) was at the core of Sputnik V. This approach was proven to be successful in creating a longer and more durable immunity against coronavirus. RDIF initiated partnerships with other vaccine producers to conduct joint studies on the combination of the first component of Sputnik V with other vaccines.
Such studies are currently ongoing in Russia, Argentina, Azerbaijan and UAE, among others.
In particular, RDIF, Ministry of Health of Argentina, Ministry of Science of Argentina and CONICET are conducting a study to evaluate the immune response and safety of heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm and Moderna in the city and province of Buenos Aires, as well as the San Luis, Cordoba and La Rioja provinces. Initial results of the study confirm a high safety profile of combinations with no serious adverse events related to vaccination.
Preliminary results of the combined use of the AstraZeneca vaccine and Sp...
(All Rights Reserved)